| Literature DB >> 21059932 |
Brian C Geyer1, Latha Kannan, Pierre-Emmanuel Garnaud, Clarence A Broomfield, C Linn Cadieux, Irene Cherni, Sean M Hodgins, Shane A Kasten, Karli Kelley, Jacquelyn Kilbourne, Zeke P Oliver, Tamara C Otto, Ian Puffenberger, Tony E Reeves, Neil Robbins, Ryan R Woods, Hermona Soreq, David E Lenz, Douglas M Cerasoli, Tsafrir S Mor.
Abstract
The concept of using cholinesterase bioscavengers for prophylaxis against organophosphorous nerve agents and pesticides has progressed from the bench to clinical trial. However, the supply of the native human proteins is either limited (e.g., plasma-derived butyrylcholinesterase and erythrocytic acetylcholinesterase) or nonexisting (synaptic acetylcholinesterase). Here we identify a unique form of recombinant human butyrylcholinesterase that mimics the native enzyme assembly into tetramers; this form provides extended effective pharmacokinetics that is significantly enhanced by polyethylene glycol conjugation. We further demonstrate that this enzyme (but not a G117H/E197Q organophosphorus acid anhydride hydrolase catalytic variant) can prevent morbidity and mortality associated with organophosphorous nerve agent and pesticide exposure of animal subjects of two model species.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21059932 PMCID: PMC2996644 DOI: 10.1073/pnas.1009021107
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205